Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone in Ischemia Reperfusion Injury (EPLICARD)
NCT02118753Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2014
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, single-blind trial of eplerenone in ischemia-reperfusion injury (IRI) (7 arms), sponsored by Radboud University Medical Center. Primary endpoint: Recovery of contractile function after simulated ischemia and reperfusion at 210 minutes. Started Mar 2014; status: completed.
02
Drugs
eplerenone
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02118753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118753.